Compare Ginkgo Bioworks Holdings Inc (DNA) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs McCormick & Company, Incorporated — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.59 (market cap $772.39M), while McCormick & Company, Incorporated trades at $45.62 (market cap $12.20B). The key difference: McCormick & Company, Incorporated is far larger — about 15.8× Ginkgo Bioworks Holdings Inc's market cap, and McCormick & Company, Incorporated pays a 4.24% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and McCormick & Company, Incorporated for 67 Days on average.
| DNA | MKC | |
|---|---|---|
Market Cap | $772.39M | $12.20B |
Volume | 6,453,273 | 4,117,008 |
Sector | Health | Consumer Staples |
52-Week High | $15.83 | $71.65 |
52-Week Low | $5.48 | $44.14 |
Typical Hold Time | 7 Days | 67 Days |
Enterprise Value | $874.34M | $16.88B |
Dividend Yield | — | 4.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
MKC trades at $45.94, up 1.19% today, with a bearish technical signal but strong fundamentals. Recent Q3 2026 earnings beat estimates with $0.86 EPS, driven by 17% sales growth and margin expansion. The stock appears undervalued with a P/E of 8.18 and offers a dividend yield. Cash flow trends show operational strength despite a net outflow in 2025.
The outlook is mixed: solid earnings growth and a $53.50 consensus price target suggest upside, but technical weakness and competitive pressures pose risks. Investor sentiment is cautious with a 'Hold' analyst consensus. Key catalysts include continued margin improvement and integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
